Voyager Therapeutics, Inc. (VYGR)
NASDAQ
Market Cap
$424.27M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
800 of 809
Rank in Industry
441 of 445
Largest Insider Buys in Sector
VYGR Stock Price History Chart
VYGR Stock Performance
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Voyager Therapeutics, Inc.
Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $641,709 worth of Voyager Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.82M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.
List of Insider Buy and Sell Transactions, Voyager Therapeutics, Inc.
| 2024-04-02 | Sale | Sandrock Alfred | President and CEO | 12,115 0.0222% | $9.86 | $119,454 | -14.93% | |
| 2024-04-02 | Sale | Swartz Robin | Chief Operating Officer | 1,357 0.0025% | $9.88 | $13,407 | -14.93% | |
| 2024-02-21 | Sale | Sandrock Alfred | President and CEO | 13,033 0.0278% | $7.46 | $97,226 | +12.17% | |
| 2024-02-21 | Sale | PFREUNDSCHUH PETER P. | Chief Financial Officer | 3,764 0.008% | $7.46 | $28,079 | +12.17% | |
| 2024-02-21 | Sale | Swartz Robin | Chief Operating Officer | 3,966 0.0084% | $7.45 | $29,547 | +12.17% | |
| 2024-02-21 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,365 0.0072% | $7.47 | $25,137 | +12.17% | |
| 2024-02-20 | Sale | Carter Todd Alfred | Chief Scientific Officer | 602 0.0013% | $7.68 | $4,623 | +13.21% | |
| 2024-01-17 | Sale | Swartz Robin | Chief Operating Officer | 2,543 0.0054% | $7.15 | $18,182 | +16.05% | |
| 2024-01-17 | Sale | Carter Todd Alfred | Chief Scientific Officer | 1,266 0.0027% | $7.18 | $9,090 | +16.05% | |
| 2023-10-03 | Sale | PFREUNDSCHUH PETER P. | Chief Financial Officer | 13,567 0.0298% | $6.99 | $94,833 | +10.99% | |
| 2023-09-15 | Sale | Carter Todd Alfred | Chief Scientific Officer | 10,500 0.0245% | $8.16 | $85,680 | -1.88% | |
| 2023-07-06 | Sale | Carter Todd Alfred | Chief Scientific Officer | 5,500 0.0137% | $10.80 | $59,400 | -22.65% | |
| 2023-06-30 | Sale | Carter Todd Alfred | Chief Scientific Officer | 5,000 0.0123% | $11.41 | $57,050 | -27.95% | |
| 2023-04-03 | Sale | Sandrock Alfred | President and CEO | 7,437 0.0187% | $7.83 | $58,232 | +2.19% | |
| 2023-04-03 | Sale | Swartz Robin | Chief Operating Officer | 1,259 0.0032% | $7.83 | $9,858 | +2.19% | |
| 2023-03-15 | Sale | Swartz Robin | Chief Operating Officer | 15,373 0.041% | $8.20 | $126,059 | +0.25% | |
| 2023-02-23 | NEUROCRINE BIOSCIENCES INC | 10 percent owner | 4.4M 14.7056% | $8.88 | $39.03M | +14.60% | ||
| 2023-02-17 | Sale | Hesslein Robert W. | Senior VP & General Counsel | 3,297 0.0086% | $7.45 | $24,563 | +6.59% | |
| 2023-02-17 | Sale | Carter Todd Alfred | Chief Scientific Officer | 738 0.0019% | $7.45 | $5,498 | +6.59% | |
| 2023-02-13 | Sale | Hesslein Robert W. | Senior VP & General Counsel | 2,868 0.0073% | $7.67 | $21,998 | +1.41% |
Insider Historical Profitability
<0.0001%
| Sandrock Alfred | President and CEO | 322839 0.4651% | $7.80 | 0 | 3 | |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 175669 0.3238% | $7.80 | 0 | 2 | |
| Swartz Robin | Chief Operating Officer | 117004 0.1567% | $7.80 | 0 | 8 | |
| Carter Todd Alfred | Chief Scientific Officer | 87627 0.1151% | $7.80 | 0 | 10 | |
| NEUROCRINE BIOSCIENCES INC | 10 percent owner | 8575316 18.5828% | $7.80 | 2 | 0 | +7.07% |
| TEPPER ROBERT I | 5428933 11.7645% | $7.80 | 0 | 3 | ||
| Third Rock Ventures III, L.P. | 10 percent owner | 4685291 10.1531% | $7.80 | 0 | 8 | |
| EcoR1 Capital, LLC | director | 3851507 8.3462% | $7.80 | 1 | 3 | +28.87% |
| Sanofi | 2477941 5.3697% | $7.80 | 1 | 0 | <0.0001% | |
| PAUL STEVEN M | President and CEO | 872351 1.8904% | $7.80 | 1 | 0 | <0.0001% |
| Turenne Andre | President & CEO | 148375 0.3215% | $7.80 | 0 | 3 | |
| Sah Dinah Ph.D. | Chief Scientific Officer | 138688 0.3005% | $7.80 | 0 | 1 | |
| Khwaja Omar | See remarks | 120509 0.2611% | $7.80 | 0 | 3 | |
| Hesslein Robert W. | Senior VP & General Counsel | 106610 0.231% | $7.80 | 0 | 10 | |
| GERAGHTY JAMES A | director | 76588 0.166% | $7.80 | 2 | 0 | <0.0001% |
| Burek Julie | VP, Finance | 52458 0.1137% | $7.80 | 0 | 5 | |
| Dorval Allison | Chief Financial Officer | 45894 0.0995% | $7.80 | 0 | 3 | |
| Higgins Michael J | 31314 0.0679% | $7.80 | 0 | 1 | ||
| Ottmer Matthew P. | Chief Operating Officer | 26276 0.0569% | $7.80 | 0 | 1 | |
| PIERCE GLENN | 16788 0.0364% | $7.80 | 1 | 1 | <0.0001% | |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 0 0% | $7.80 | 0 | 4 | |
| Ravina Bernard | Chief Medical Officer | 0 0% | $7.80 | 0 | 10 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Armistice Capital Llc | $43.5M | 8.59 | 4.67M | +10.29% | +$4.06M | 0.52 | |
| BlackRock | $40.94M | 8.08 | 4.4M | +67.03% | +$16.43M | <0.01 | |
| Ecor1 Capital Llc | $36.47M | 7.2 | 3.92M | +1.72% | +$614,823.09 | 0.93 | |
| The Vanguard Group | $30.09M | 5.94 | 3.23M | +27.75% | +$6.54M | <0.01 | |
| Farallon Capital | $21.34M | 4.21 | 2.29M | +77.4% | +$9.31M | 0.15 | |
| State Street | $16.28M | 3.22 | 1.75M | +182.21% | +$10.51M | <0.01 | |
| Dimensional Fund Advisors | $10.29M | 2.03 | 1.11M | +18.59% | +$1.61M | <0.01 | |
| T. Rowe Price | $9.7M | 1.92 | 1.04M | +3.7% | +$345,868.81 | <0.01 | |
| Geode Capital Management | $9.05M | 1.79 | 972,364 | +43.23% | +$2.73M | <0.01 | |
| AQR Capital | $7.39M | 1.46 | 793,634 | +24.14% | +$1.44M | 0.01 | |
| American Century Investments | $7.17M | 1.42 | 769,673 | +63.68% | +$2.79M | <0.01 | |
| Federated Hermes | $5.14M | 1.01 | 551,576 | 0% | +$0 | 0.01 | |
| Acadian Asset Management | $4.28M | 0.85 | 459,850 | +10.06% | +$391,179.99 | 0.02 | |
| Northern Trust | $3.63M | 0.72 | 389,816 | +23.76% | +$696,853.51 | <0.01 | |
| Goldman Sachs | $3.55M | 0.7 | 381,709 | +112.03% | +$1.88M | <0.01 | |
| Bank of America | $3.3M | 0.65 | 354,443 | +4,501.96% | +$3.23M | <0.0001 | |
| JPMorgan Chase | $2.95M | 0.58 | 316,655 | -2.12% | -$63,987.63 | <0.0001 | |
| GlobeFlex Capital | $2.88M | 0.57 | 309,508 | -6.58% | -$202,790.39 | 0.28 | |
| Woodline Partners LP | $2.79M | 0.55 | 300,000 | New | +$2.79M | 0.03 | |
| Morgan Stanley | $2.63M | 0.52 | 282,160 | +15.94% | +$361,060.61 | <0.0001 | |
| Fiduciary Trust Co | $2.41M | 0.48 | 259,397 | 0% | +$0 | 0.04 | |
| Kestra Advisory Services LLC | $2.39M | 0.47 | 256,449 | +18.68% | +$375,826.05 | 0.02 | |
| BNY Mellon | $2.33M | 0.46 | 250,131 | -1.1% | -$25,844.60 | <0.0001 | |
| D. E. Shaw & Co. | $2.18M | 0.43 | 233,989 | -42.37% | -$1.6M | <0.01 | |
| Wellington Management Company | $1.9M | 0.38 | 204,029 | New | +$1.9M | <0.0001 | |
| Ikarian Capital LLC | $1.68M | 0.33 | 180,857 | -40.87% | -$1.16M | 0.48 | |
| Bridgeway Capital Management | $1.67M | 0.33 | 179,771 | -0.57% | -$9,542.75 | 0.03 | |
| Td Asset Management Inc | $1.51M | 0.3 | 161,928 | +21.29% | +$264,646.12 | <0.01 | |
| Massachusetts Financial Services Co Ma | $1.29M | 0.26 | 138,707 | +25.05% | +$258,641.08 | <0.0001 | |
| First Trust | $1.29M | 0.25 | 138,129 | +60.92% | +$486,819.53 | <0.01 | |
| CAPTRUST | $1.2M | 0.24 | 129,003 | +412.91% | +$966,862.18 | <0.0001 | |
| Renaissance Technologies | $1.19M | 0.24 | 128,100 | -30.04% | -$512,217.02 | <0.01 | |
| Advantage Alpha Capital Partners Lp | $1.14M | 0.23 | 122,311 | -30.85% | -$507,953.42 | 0.22 | |
| Rafferty Asset Management Llc | $1.11M | 0.22 | 119,216 | New | +$1.11M | <0.01 | |
| Charles Schwab | $1.07M | 0.21 | 114,452 | +35.07% | +$276,646.62 | <0.0001 | |
| Franklin Templeton Investments | $1M | 0.2 | 107,921 | +664.21% | +$873,268.25 | <0.0001 | |
| Citigroup | $983,071.00 | 0.19 | 105,593 | +1,868.92% | +$933,141.46 | <0.01 | |
| UBS | $970,884.00 | 0.19 | 104,284 | +218.97% | +$666,502.87 | <0.0001 | |
| Millennium Management LLC | $937,750.00 | 0.19 | 100,725 | New | +$937,750.00 | <0.01 | |
| ClariVest Asset Management LLC | $932,145.00 | 0.18 | 100,123 | +59.31% | +$347,030.20 | 0.1 | |
| Allspring Global Investments | $924,539.00 | 0.18 | 99,306 | +2.09% | +$18,899.30 | <0.01 | |
| AXA | $921,690.00 | 0.18 | 99,000 | 0% | +$0 | <0.01 | |
| Cubist Systematic Strategies | $879,311.00 | 0.17 | 94,448 | New | +$879,311.00 | 0.01 | |
| The Manufacturers Life Insurance Company | $828,897.00 | 0.16 | 89,033 | +13.74% | +$100,147.64 | <0.01 | |
| Nuveen | $831,988.00 | 0.16 | 89,365 | 0% | +$0 | <0.0001 | |
| Summerhaven Investment Management Llc | $701,713.00 | 0.14 | 75,372 | +1.65% | +$11,414.06 | 0.45 | |
| Winton Capital Management | $693,697.00 | 0.14 | 74,511 | +63.65% | +$269,794.33 | 0.04 | |
| Man Group Plc | $681,762.00 | 0.14 | 73,229 | +352.95% | +$531,247.23 | <0.01 | |
| Deutsche Bank | $669,454.00 | 0.13 | 71,907 | +9.3% | +$56,986.50 | <0.0001 | |
| Aviva | $654,353.00 | 0.13 | 70,285 | -15.1% | -$116,356.32 | <0.01 |